Welcome to
On Feet Nation
The global Nucleic Acid Therapeutics CDMO Market size is expected to reach USD 33.86 billion by 2030, registering a CAGR of 14.10% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.
Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.
The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.
Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).
The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.
List of Key Players in the Nucleic Acid Therapeutics CDMO Market
Related Press Release@ Nucleic Acid Therapeutics CDMO Market Report
Nucleic Acid Therapeutics CDMO Market Report Highlights
Report Attribute |
Details |
Market size value in 2024 |
USD 15.35 billion |
Revenue forecast in 2030 |
USD 33.86 billion |
Growth rate |
CAGR of 14.10% from 2024 to 2030 |
Base year for estimation |
2023 |
Historical data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Inquire @ https://www.grandviewresearch.com/inquiry/455661/ibb
Nucleic Acid Therapeutics CDMO Market Segmentation
Grand View Research has segmented the global nucleic acid therapeutics CDMO market report based on type, service, end-use, application, and region:
Nucleic Acid Therapeutics CDMO Type Outlook (Revenue, USD Million, 2018 - 2030)
Nucleic Acid Therapeutics CDMO Service Outlook (Revenue, USD Million, 2018 - 2030)
Nucleic Acid Therapeutics CDMO End Use Outlook (Revenue, USD Million, 2018 - 2030)
Nucleic Acid Therapeutics CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)
Nucleic Acid Therapeutics CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)
Explore Horizon, the world's most expansive market research database
© 2024 Created by PH the vintage.
Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation